Compare STEM & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEM | NRXS |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 78.9M |
| IPO Year | 2020 | 2023 |
| Metric | STEM | NRXS |
|---|---|---|
| Price | $9.42 | $6.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.33 | $13.00 |
| AVG Volume (30 Days) | 107.0K | ★ 213.9K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,266,000.00 | $3,569,282.00 |
| Revenue This Year | $3.43 | $172.91 |
| Revenue Next Year | $13.92 | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.08 | ★ 32.89 |
| 52 Week Low | $0.29 | $1.33 |
| 52 Week High | $32.23 | $7.97 |
| Indicator | STEM | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 50.57 |
| Support Level | $8.12 | $6.44 |
| Resistance Level | $10.99 | $7.97 |
| Average True Range (ATR) | 0.71 | 0.63 |
| MACD | 0.15 | -0.10 |
| Stochastic Oscillator | 48.43 | 27.21 |
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).